Dr. Stoxx
Stock Trader & Author, Oxford DPhil, Trading Education
UnitedHealth's potential earnings recovery and margin expansion offer a fundamental case for its emerging Stage 2 uptrend. EPS is expected to grow 53%, from $20.47 in 2026 to $31.31 by 2029, while revenue is projected to rise from $448B to $511B; a weekly bull flag has broken out. x.comÂ
UnitedHealth's collapse was driven more by fear than fundamentals, making it one of the biggest opportunities in years, reminiscent of Meta in 2022. Fraud accusations led nowhere as the DOJ dropped its investigation, and peers Humana and CVS recovered from the same cost underestimation and beat later. With over $420B in revenue and deep ties to US employers, UnitedHealth is too big to fail and could survive even a fine. That same logic pointed to Berkshire being the undisclosed buyer. x.comÂ
UnitedHealth's earnings visibility, unusually high dividend yield and resumed buybacks make paying under 16x forward earnings not look terrible. Still reasonably confident it is a good place to hide for long-term capital: Hemsley keeps clearing the bar, and UnitedHealth has beaten and raised guidance for three straight quarters. Further derisking remains a risk. x.com x.com x.comÂ
UnitedHealth could be a $600 stock over the next three to five years if margins stabilize, a solid return from here, as the market remembers why it has been a strong long-term compounder. It has scale, Optum, insurance exposure and durable cash flow; the stock was hit by medical-cost pressure, regulation and sentiment, but the business still generates a lot of cash. SoFi and ServiceNow offer more upside, with three-year targets of $80+ and $300+. x.com x.comÂ
Healthcare is the clearest place money is moving, and UnitedHealth is the preferred name here. It beat earnings and raised its 2026 profit forecast. x.comÂ
UnitedHealth collects ever-rising US healthcare spending, and its stock has stopped falling. Family plan costs rose 249% in two decades toward $24,000, US spending nears $10,000 a person, and the over-65 population is set to double to two billion by 2050. After earnings fell 59% and 69% in back-to-back quarters and the stock dropped from 606 to 248, it based near 250 for a year, a Weinstein Stage 1, then reclaimed its moving average and pushed above 400. x.com x.com x.com x.comÂ
UnitedHealth may be making a rare episodic pivot for a stock its size, coming off an earnings beat. The stock is incredibly undervalued. x.comÂ
UnitedHealth is cheap against its earnings at about 17 times next year's, while health insurers usually get 20 times. Twenty times next year's estimated $22.55 per share, give or take 12%, puts fair value at about $396.80-$505.02, above the $376.30 price; it turns expensive above $435.96. The forward read leans on a forecast 45% above trailing earnings. This is a levels-only screen off reported earnings and revenue estimates, with no fundamental work. x.comÂ
UnitedHealth remains essential to the US economy and still provides the best pay-and-collect mechanism for doctors and hospitals in the country. Per CNBC, its first-quarter adjusted EPS of $7.23 beat expectations of $6.57, and it raised its full-year earnings outlook. x.comÂ
UnitedHealth should outperform through year-end on midterm-year seasonality and as a defensive leader if markets weaken. Over the last 20 years, healthcare has generally done well from July through December in midterm years, and if the S&P 500 rolls into a bear market, investors should rotate into defensives led by UNH. The bull case also rests on AI and GLP-1 use lowering the medical cost ratio and institutions returning to healthcare. The war has made everything more volatile. x.comÂ